PLUVICTO Can Be Administered Multiple Ways and Is Administered Once Every 6 Weeks for 6 Doses¹

Dosing¹

PLUVICTO solution for injection contains 7.4 GBq (200 mCi ± 10%) (at time of use)
Slow IV injection (1 to 10 minutes) or infusion
Pre-filled syringe

PLUVICTO infusion vial and pre-filled syringe

6 treatments, 6 weeks apart. Injections last less than 10 minutes.

The median number of doses of PLUVICTO in the PSMAddition trial in mAPMN/S PC (mHSPC) (+ ARPI) was 6¹

85.6% of patients received all 6 doses²
- The recommended dosage of PLUVICTO in combination with ARPI is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity¹

The median number of doses of PLUVICTO in the PSMAfore trial in mAPMR PC (mCRPC) after only 1 ARPI was 6¹

63% of patients received 6 doses³
- The recommended dosage of PLUVICTO is 7.4 GBq (200 mCi) every 6 weeks for 6 doses, or until disease progression or unacceptable toxicity¹
Patients receiving PLUVICTO for metastatic prostate cancer should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy¹

ARPI, androgen receptor pathway inhibitor; GBq, gigabecquerel; IV, intravenous; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCi, millicurie; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer.

Watch Dr Vaishampayan, Dr Reichard, and Dr Franklin share best practices for a multidisciplinary team when providing treatment with PLUVICTO below.

Dose Modifications

DOSE MODIFICATIONS FOR ADVERSE REACTIONS¹

Management of adverse reactions may require temporary dose interruption, dose reduction, or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an adverse reaction persists for >4 weeks, consider permanent discontinuation of PLUVICTO.

Recommended dosage modifications of PLUVICTO for adverse reactions¹

CrCl, creatinine clearance.
Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE).

Administration

SETUP AND ADMINISTRATION OF PLUVICTO¹

General information

PLUVICTO is administered intravenously
Nuclear medicine health care professionals may use methods deemed appropriate and safe
Prior to administration with PLUVICTO, a saline flush with ≥10 mL of 0.9% sterile sodium chloride must be administered to ensure patency of the IV line and minimize the risk of extravasation
Manage cases of extravasation as per your institutional guidelines
PLUVICTO will be administered slowly by intravenous route and followed by a saline flush

Radiation Safety

IMPORTANT NOTE REGARDING USE OF PLUVICTO⁴

Always use the principles of ALARA (as low as reasonably achievable)

ALARA is the guiding principle of radiation safety. It means that even a small radiation dose should be avoided if there is no benefit to receiving it. It includes 3 basic protective measures:

Minimize time spent near radioactive source, maximize distance, and use shielding between yourself and radioactive source

Any unused medicinal product or waste material should be disposed of in accordance with local and federal laws.¹

PLUVICTO Administration Guide

Find information on radiation safety, recommended dosing for PLUVICTO, administration, patient counseling, and more.

Download

How to Communicate PLUVICTO Safety With Your Patients

How to Communicate PLUVICTO Radiation Safety With Your Patients

Radiation oncologist Glen Gejerman, MD, MBA, presenting at a live event, provides insights and best practices for communicating radiation safety with patients receiving PLUVICTO.

Operationalizing PLUVICTO in Metastatic APMN/S Prostate Cancer (mHSPC): A Medical Oncologist’s Perspective

Medical oncologist Jahan Aghalar, MD, discusses clinical considerations for operationalizing PLUVICTO in PSMA‑positive mAPMN/S prostate cancer (mHSPC), including multidisciplinary coordination, workflow, and referral pathways.

Best Practices in Providing Treatment as a Multidisciplinary Team

Ulka Vaishampayan, MD, with Chad Reichard, MD, and Gregg Franklin, MD, PhD, share best practices in patient care and key PLUVICTO administration considerations, highlighting a multidisciplinary approach for patients with mAPMR prostate cancer (mCRPC ).

Choosing the Optimal Therapy Early for Patients With Metastatic APMR Prostate Cancer (mCRPC)

MEs sharing first‑hand referral experiences and the key moments that led them to choose PLUVICTO, reinforcing triggers for mAPMR prostate cancer (mCRPC) referral and easing common HCP concerns.

Providing PLUVICTO at the Earliest Eligible Opportunity for Patients With Metastatic APMR Prostate Cancer (mCRPC)

MEs sharing first‑hand referral experiences and the key moments that led them to choose PLUVICTO, reinforcing triggers for mAPMR prostate cancer (mCRPC) referral and easing common HCP concerns.

Plan early to be ready for what’s next

View the mCRPC data View the mHSPC data

< Previous: Safety

Next: Access and Support >

PLUVICTO Can Be Administered Multiple Ways and Is Administered Once Every 6 Weeks for 6 Doses¹